Zymeworks ZYME 深 沪
等待开盘 10-09 09:30:00 美东时间
25.26
-1.270
-4.79%
华盛通- 最 高26.24
- 今 开26.24
- 成交量 125.82万股
- 最 低 25.00
- 昨 收 26.53
- 总市值 181.24万
- 52周最高 31.34
- 市盈率 静 --
- 换手率 1753.60%
- 52周最低 16.0034
- 委 比 89.96%
- 总股本 7.18万
- 历史最高 59.03
- 量 比 1.09
- 振 幅 4.67%
- 历史最低 4.11
- 每 手 1
- 风险率 2.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $32 to $34.
10-08 01:21
Nuvation, Jazz gain new Buys at Citi on oncology prospects
Citi launched its coverage of Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings on Wednesday as part of a broader review of the U.S. biopharma sector, highlighting the companies' on...
10-01 01:47
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $38 to $39.
09-30 01:59
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma appointed Lucas Donigian as Senior Vice President, Business Development, leveraging his 20+ years of biotech experience, including over $2B in oncology partnerships. Donigian will help advance Sutro’s ADC platform and pipeline, including STRO-004, STRO-006, and STRO-227, while building strategic collaborations. He previously led business development at Zymeworks and NanoString Technologies. Sutro granted Donigian stock options and...
09-29 12:00
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks Inc. (NASDAQ:ZYME) on Monday finalized its acquisition of Theravance Biopharma, releasing final transaction details and updated financial guidance for fiscal year 2026. The biotechnology company projects 2026 revenue between $278 million and $292 million, alongside 2026 adjusted EBITDA ran...
09-29 01:05
Zymeworks outlines guidance following Theravance acquisition
Zymeworks (ZYME) Monday reported the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma. The acquisition adds YUPELRI (revefen...
09-28 18:51
Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est
Zymeworks (NASDAQ:ZYME) sees FY2026 sales of $278.000 million-$292.000 million vs $302.577 million analyst estimate.
09-28 18:20
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisi...
09-28 18:12
